Science & Technology
Development of a novel, RNA-interference-based therapeutic to treat prostate cancer
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41CA287846-01A1
Award Ceiling
$400K
Award Floor
$400K
Close Date
Aug 31, 2025
Total Funding
$400K
Expected Awards
1
Posted Date
Sep 19, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R41CA287846-01A1
Description
STTR Phase Phase I award: "Development of a novel, RNA-interference-based therapeutic to treat prostate cancer" awarded to NUAGO THERAPEUTICS INC in CHICAGO, Illinois. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $400,000. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.